February 28, 2024
Postmenopausal Osteoporosis Market

Postmenopausal Osteoporosis Market is Expected to be Flourished by Increasing Awareness about Treatments

Postmenopausal osteoporosis refers to osteoporosis that develops after menopause. It is common among women after menopause. The bones become weak and brittle, so they break easily. It is characterized by low bone mass and structural deterioration of bone tissue leading to bone fragility and an increased susceptibility to fractures. Common symptoms include back pain caused by fractured or compressed vertebrae and loss of height over time. The global postmenopausal osteoporosis market is expected to grow significantly in the coming years due to the increasing awareness about the effective treatments available for postmenopausal osteoporosis.

The global Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4747.9 Mn in 2023 and is expected to exhibit a CAGR of 67% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Increasing awareness about treatments is expected to drive growth of the postmenopausal osteoporosis market over the forecast period. Various governments and non-profit organizations worldwide are undertaking various initiatives and campaigns to increase awareness about osteoporosis, its risk factors, preventive measures, screening, and treatment options available. This is likely to encourage more number of post-menopausal women to seek medical help and get proper treatment.

Another major driver for the market growth is the flourishing drug pipeline. Numerous pharmaceutical companies are focusing on developing novel therapeutics for osteoporosis with improved efficacy and better safety profiles. Several drug candidates are under clinical trials which upon approval will provide new treatment alternatives to physicians and patients. This is anticipated to fuel the market growth during the forecast period.

Segment Analysis
The global postmenopausal osteoporosis market is segmented into drug class and distribution channel. Based on drug class, the market is segmented into bisphosphonates, hormonal therapy, selective estrogen receptor modulators (SERMs), calcitonin, and others. Currently, bisphosphonates dominate the market owing to their high efficacy. Bisphosphonates are considered the standard first-line treatment and have been shown to reduce the risk of fracture in postmenopausal women.

PEST Analysis
Political: Regulations promoting awareness about postmenopausal osteoporosis and its treatment are driving the market growth. However, patent expirations of blockbuster drugs pose challenges.
Economic: Rising healthcare spending, growing geriatric population, and economic development are fueling the market expansion.
Social: Increasing incidence of osteoporosis due to sedentary lifestyles and aging population is boosting the demand. Support groups are creating awareness about the condition.
Technological: Advancements in drug delivery systems and novel anabolics are widening treatment options. New mechanisms of action are being explored to overcome limitations of existing therapies.

Key Takeaways
Global Postmenopausal Osteoporosis Market Size is expected to witness high growth over the forecast period supported by aging population, increasing incidence of osteoporosis among postmenopausal women, and robust pipeline of drugs in late stages of development.

Regional analysis: North America currently dominates the market and is expected to continue its dominance owing to growing elderly population, rising healthcare expenditure, and availability of advanced treatment options. However, Asia Pacific is anticipated to observe fastest growth owing to increasing patient pool, growth of medical tourism, and rise in health awareness.

Key players: Key players operating in the postmenopausal osteoporosis market are IBM Research, Inc., Knowm Inc., Intel Corp., BrainChip Holdings Ltd., General Vision Inc., HRL Laboratories, LLC, Qualcomm Technologies Inc., and Hewlett Packard Labs. These companies are focusing on developing novel bone-building therapies and osteoanabolic drugs to treat postmenopausal osteoporosis more effectively.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it